[Prostaglandin E2 in newborns with congenital heart disease]. 1982

M Schlemmer, and A Khoss, and H R Salzer, and M Wimmer

Prostaglandins of the E-type are potent ductus dilatators not only in vitro but also in vivo, as could be shown in the former literature. We report on 20 newborn children, in whom we only used prostaglandin E2 to perform a better lung or kidney perfusion by opening the ductus arteriosus. The diagnoses of the children were: pulmonary atresia + ventricular septal defect +/- transposition of the aorta, tricuspid atresia, hypoplastic left heart syndrome, transposition of the great arteries +/- ventricular septal defect, coarctation of the aorta and tetralogy of Fallot. The dosis pattern of the prostaglandin E2 infusion was in 17 patients the same, starting with 0.1 microgram/kg body weight/min and consecutive reduction depending on the capillary pO2, in the last 3 patients we started with 0.05 microgram/kg body weight/min. In 7 patients we gave an oral preparation of prostaglandin E2 intermittently. The duration of treatment was between 15 min and 37 days. There was a significant increase of the capillary pO2 under prostaglandin E2 treatment (p less than 0.0001), the increase of capillary pO2 correlates negatively with the initial pO2 before treatment (p less than 0.05), but there is no dependence on the age of the children. The side effects of this therapy are discussed, especially the dangerous apnoic spells.

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D011458 Prostaglandins E (11 alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid (PGE(1)); (5Z,11 alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid (PGE(2)); and (5Z,11 alpha,13E,15S,17Z)-11,15-dihydroxy-9-oxoprosta-5,13,17-trien-1-oic acid (PGE(3)). Three of the six naturally occurring prostaglandins. They are considered primary in that no one is derived from another in living organisms. Originally isolated from sheep seminal fluid and vesicles, they are found in many organs and tissues and play a major role in mediating various physiological activities. PGE
D002621 Chemistry A basic science concerned with the composition, structure, and properties of matter; and the reactions that occur between substances and the associated energy exchange.
D006330 Heart Defects, Congenital Developmental abnormalities involving structures of the heart. These defects are present at birth but may be discovered later in life. Congenital Heart Disease,Heart Abnormalities,Abnormality, Heart,Congenital Heart Defect,Congenital Heart Defects,Defects, Congenital Heart,Heart Defect, Congenital,Heart, Malformation Of,Congenital Heart Diseases,Defect, Congenital Heart,Disease, Congenital Heart,Heart Abnormality,Heart Disease, Congenital,Malformation Of Heart,Malformation Of Hearts
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D015232 Dinoprostone The most common and most biologically active of the mammalian prostaglandins. It exhibits most biological activities characteristic of prostaglandins and has been used extensively as an oxytocic agent. The compound also displays a protective effect on the intestinal mucosa. PGE2,PGE2alpha,Prostaglandin E2,Prostaglandin E2alpha,PGE2 alpha,Prepidil Gel,Prostaglandin E2 alpha,Prostenon,E2 alpha, Prostaglandin,E2, Prostaglandin,E2alpha, Prostaglandin,Gel, Prepidil,alpha, PGE2,alpha, Prostaglandin E2
D055598 Chemical Phenomena The composition, structure, conformation, and properties of atoms and molecules, and their reaction and interaction processes. Chemical Concepts,Chemical Processes,Physical Chemistry Concepts,Physical Chemistry Processes,Physicochemical Concepts,Physicochemical Phenomena,Physicochemical Processes,Chemical Phenomenon,Chemical Process,Physical Chemistry Phenomena,Physical Chemistry Process,Physicochemical Phenomenon,Physicochemical Process,Chemical Concept,Chemistry Process, Physical,Chemistry Processes, Physical,Concept, Chemical,Concept, Physical Chemistry,Concept, Physicochemical,Concepts, Chemical,Concepts, Physical Chemistry,Concepts, Physicochemical,Phenomena, Chemical,Phenomena, Physical Chemistry,Phenomena, Physicochemical,Phenomenon, Chemical,Phenomenon, Physicochemical,Physical Chemistry Concept,Physicochemical Concept,Process, Chemical,Process, Physical Chemistry,Process, Physicochemical,Processes, Chemical,Processes, Physical Chemistry,Processes, Physicochemical

Related Publications

M Schlemmer, and A Khoss, and H R Salzer, and M Wimmer
April 1981, Pediatric annals,
M Schlemmer, and A Khoss, and H R Salzer, and M Wimmer
May 1987, European journal of pediatrics,
M Schlemmer, and A Khoss, and H R Salzer, and M Wimmer
January 2016, Pediatric cardiology,
M Schlemmer, and A Khoss, and H R Salzer, and M Wimmer
October 1988, Acta paediatrica Japonica : Overseas edition,
M Schlemmer, and A Khoss, and H R Salzer, and M Wimmer
January 2010, Congenital heart disease,
M Schlemmer, and A Khoss, and H R Salzer, and M Wimmer
February 2022, Pediatric research,
M Schlemmer, and A Khoss, and H R Salzer, and M Wimmer
March 1983, Archives of disease in childhood,
M Schlemmer, and A Khoss, and H R Salzer, and M Wimmer
January 2016, The Journal of perinatal & neonatal nursing,
M Schlemmer, and A Khoss, and H R Salzer, and M Wimmer
May 2014, Annals of pediatric cardiology,
M Schlemmer, and A Khoss, and H R Salzer, and M Wimmer
January 1993, Journal of intensive care medicine,
Copied contents to your clipboard!